ip
eline drugs in the Primary Progressive Multiple Sclerosis pipeline landscapes. It comprises PPMS pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Primary Progressive Multiple Sclerosis therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive PPMS pipeline products.
Some of the crucial features of the Primary Progressive Multiple Sclerosis key players such as
Atara Biotherapeutics, MediciNova, AB Science, and many others involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects. Different therapeutic candidates are segmented into early-stage, mid-stage, and late-stage of development for the PPMS treatment.
100+
pipeline drugs in the Diffuse Large B Cell Lymphoma pipeline landscape. It comprises DLBCL pipeline drug profiles, including clinical and non-clinical stage products. It also includes the Diffuse Large B Cell Lymphoma therapeutics assessment by product type, stage, route of administration, and molecule type, and further highlights the inactive DLBCL pipeline products.
Some of the significant
Highlights Several prominent companies such as ADC Therapeutics, BeiGene, Nordic Nanovector, bluebird bio, Celgene, GlaxoSmithKline, AbbVie, Roche and many others are working to assess challenges and seek opportunities that could influence Diffuse Large B-cell Lymphoma R&D. The DLBCL pipeline therapies are focused on novel approaches for the treatment.
Catherine Tomlinson Share According to the WHO’s report, chest X-ray screening is more effective at detecting TB than the traditionally used four-symptom screen
About 10 million people developed TB last year.
It is the leading cause of death by an infectious disease globally, causing 1.4 million fatalities last year – although deaths due to the Covid-19 coronavirus will most likely surpass deaths from TB this year.
While there are many factors that contribute to the high rates of TB infections and deaths, failing to diagnose many people living with TB and provide them with appropriate treatment is a key contributor to both the spread of TB and the high number of deaths.